NKTX 250117 2.50P (NKTX250117P2500) Stock Options, News & Quotes

0.10
+0.05+100.00%

15min DelayClose Jan 17 16:00 ET

0.10High0.10Low

SymbolStock Name

PriceChg% ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D % Chg10D % Chg20D % Chg60D % Chg120D % Chg250D % Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry

WatchlistPaper Trade

Comments

Jaguar8

Dec 13, 2024 18:10

🕛Watchlist MONDAY December 16. NFA. Trade the chart. Be kind… in progress

$Gorilla Technology (GRRR.US)$ PR: CEO will have interview with Red Chip Small Stock, Big Money show on Sat Dec 14. Reports on CEO on X that they have been selected from the shortlist for the $438M deal in SE Asia. Low float. $23.2M cash good for 12 months
$Checkpoint Therapeutics (CKPT.US)$ $Fortress Biotech (FBIO.US)$ FDA approval of drug for metastatic cutaneous squamous cell carcinoma. This drug is the first and only progr...

Jaguar8

Dec 13, 2024 17:39

This is good for MONDAY for me. NFA

$Nkarta (NKTX.US)$

Jaguar8

Dec 13, 2024 16:12

13G

$Nkarta (NKTX.US)$
Nkarta | SC 13G: Statement of acquisition of beneficial ownership by individuals-Kenneth Griffin(5.4%),Citadel Advisors LLC(4.5%), etc.

70205719

Dec 10, 2024 14:35

$Nkarta (NKTX.US)$
morning star? bottom now with big vol. buy now?

Jaguar8

Dec 5, 2024 05:09

NEWS

$Nkarta (NKTX.US)$
Nkarta Announces IND Clearance of Investigator-Sponsored Trial in Myasthenia Gravis and Opening of Enrollment for Ntrust-2
Nkarta (NKTX) announced the opening of enrollment for Ntrust-2 and IND clearance for an investigator-sponsored trial (IST) evaluating NKX019, their allogeneic CD19-directed CAR NK-cell therapy. Ntrust-2 will evaluate the treatment across three parallel cohorts: systemic sclerosis, myositis, and ANCA-associated vasculitis. The IST will study NKX019 in my...